OBJECTIVE: We here determine the role of IgM antibodies against phosphorylcholine (anti-PC) in prediction of cardiovascular disease (CVD) and on macrophage uptake of Oxidized LDL (OxLDL). METHODS: From a screening of 4232 subjects, 60-year-old (2039 men and 2193 women), 211 incident cases of CVD (myocardial infarction, ischemic stroke, or hospitalized angina pectoris) and 633 age- and sex-matched controls were identified through a 5-7 year follow-up. Serum levels of IgM anti-PC was determined by ELISA. Anti-PC was extracted from pooled human IgM and the effect of anti-PC on the uptake of OxLDL was studied by FACScan. RESULTS: Relative risks (RR) with 95% confidence intervals (CI) by quartiles of anti-PC levels with quartile 4 set as the reference value (RR = 1.0) and adjusted for smoking, BMI, type II diabetes, hypercholesterolaemia, and high blood pressure yielded an excess risk for CVD only for those within the lowest quartile of anti-PC values with an RR of 1.37 (CI 0.87-2.16). However, for men stronger associations were noted with increasing multivariately adjusted RRs from quartile 4 to quartile 1. Subjects within quartile 1 (values below 29.7 U/ml) had a significantly increased RR of 1.96 (CI 1.09-3.55). Further adjustments for hsCRP gave essentially the same results. No excess risk was noted for women. Specific anti-PC could be extracted from IgM and these antibodies inhibited macrophage uptake of OxLDL. CONCLUSIONS: Low IgM anti-PC could be a novel risk marker for CVD among men. One possible mechanism could be inhibition of uptake of oxLDL in macrophages. Copyright 2009 Elsevier Ltd. All rights reserved.
OBJECTIVE: We here determine the role of IgM antibodies against phosphorylcholine (anti-PC) in prediction of cardiovascular disease (CVD) and on macrophage uptake of Oxidized LDL (OxLDL). METHODS: From a screening of 4232 subjects, 60-year-old (2039 men and 2193 women), 211 incident cases of CVD (myocardial infarction, ischemic stroke, or hospitalized angina pectoris) and 633 age- and sex-matched controls were identified through a 5-7 year follow-up. Serum levels of IgM anti-PC was determined by ELISA. Anti-PC was extracted from pooled human IgM and the effect of anti-PC on the uptake of OxLDL was studied by FACScan. RESULTS: Relative risks (RR) with 95% confidence intervals (CI) by quartiles of anti-PC levels with quartile 4 set as the reference value (RR = 1.0) and adjusted for smoking, BMI, type II diabetes, hypercholesterolaemia, and high blood pressure yielded an excess risk for CVD only for those within the lowest quartile of anti-PC values with an RR of 1.37 (CI 0.87-2.16). However, for men stronger associations were noted with increasing multivariately adjusted RRs from quartile 4 to quartile 1. Subjects within quartile 1 (values below 29.7 U/ml) had a significantly increased RR of 1.96 (CI 1.09-3.55). Further adjustments for hsCRP gave essentially the same results. No excess risk was noted for women. Specific anti-PC could be extracted from IgM and these antibodies inhibited macrophage uptake of OxLDL. CONCLUSIONS: Low IgM anti-PC could be a novel risk marker for CVD among men. One possible mechanism could be inhibition of uptake of oxLDL in macrophages. Copyright 2009 Elsevier Ltd. All rights reserved.
Authors: David Frescas; Christelle M Roux; Semra Aygun-Sunar; Anatoli S Gleiberman; Peter Krasnov; Oleg V Kurnasov; Evguenia Strom; Lauren P Virtuoso; Michelle Wrobel; Andrei L Osterman; Marina P Antoch; Vadim Mett; Olga B Chernova; Andrei V Gudkov Journal: Proc Natl Acad Sci U S A Date: 2017-02-13 Impact factor: 11.205
Authors: Christian A Gleissner; Christian Erbel; Julia Haeussler; Mohammadreza Akhavanpoor; Gabriele Domschke; Fabian Linden; Andreas O Doesch; Göran Conradson; Sebastian J Buss; Nina P Hofmann; Gitsios Gitsioudis; Hugo A Katus; Grigorios Korosoglou Journal: Clin Res Cardiol Date: 2014-08-08 Impact factor: 5.460
Authors: Kelly Khomtchouk; Sarah Alter; Michelle Ratliff; Bonnie B Blomberg; Richard L Riley Journal: Mech Ageing Dev Date: 2016-11-19 Impact factor: 5.432
Authors: Xu Chen; Stefan Gustafsson; Thomas Whitington; Yan Borné; Erik Lorentzen; Jitong Sun; Peter Almgren; Jun Su; Robert Karlsson; Jie Song; Yi Lu; Yiqiang Zhan; Sara Hägg; Per Svensson; Karin E Smedby; Susan L Slager; Erik Ingelsson; Cecilia M Lindgren; Andrew P Morris; Olle Melander; Thomas Karlsson; Ulf de Faire; Kenneth Caidahl; Gunnar Engström; Lars Lind; Mikael C I Karlsson; Nancy L Pedersen; Johan Frostegård; Patrik K E Magnusson Journal: Hum Mol Genet Date: 2018-05-15 Impact factor: 6.150
Authors: Jeroen D Langereis; Amelieke J H Cremers; Marloes Vissers; Josine van Beek; Jacques F Meis; Marien I de Jonge Journal: Infect Immun Date: 2019-01-24 Impact factor: 3.441
Authors: Bram J Geller; Jessica L Mega; David A Morrow; Jianping Guo; Elaine B Hoffman; C Michael Gibson; Christian T Ruff Journal: J Thromb Thrombolysis Date: 2014-04 Impact factor: 2.300
Authors: A G Frostegård; X Hua; J Su; J J Carrero; O Heimbürger; P Bárány; P Stenvinkel; J Frostegård Journal: Clin Exp Immunol Date: 2013-12 Impact factor: 4.330